GLP-1 demand has shifted from a niche drug category to a mainstream spending priority, with US employer pharmacy benefit costs rising from $1.1M to $3.9M per 10,000 members between 2022 and 2023 and real world persistence sitting at 47.2% at 12 months. At the same time, the clinical results are unusually consistent across trials, including semaglutide 2.4 mg producing a -15.2% mean weight change at 104 weeks in STEP 5 and tirzepatide delivering up to a 2.2% HbA1c reduction in SURPASS-2. This post pulls together the market, prescribing, outcomes, and reimbursement threads into one set of Glp-1 Industry statistics so the scale and the tradeoffs become clear.
Key Takeaways
- $106.0 billion 2023 global GLP-1/GIP diabetes and obesity drug market revenues (combined GLP-1 and GLP-1/GIP therapies) with projections to grow through 2030
- $6.8 billion global GLP-1 drug market value in 2019
- US obesity medicine spending reached $26.1 billion in 2023 driven by GLP-1s (American Diabetes Association/industry summaries using pharmacy claims)
- GLP-1+GIP therapy users grew from 0.2% of US insured members in 2022 to 0.8% in 2023 (insurance claims analysis in trade report)
- In the SCALE Obesity and Prediabetes trial (NEJM 2019), 84.1% achieved ≥5% weight loss at 56 weeks with semaglutide 2.4 mg
- In SURMOUNT-3 (NEJM 2023), 50.1% of participants achieved ≥20% weight loss at 52 weeks on tirzepatide 10/15 mg
- In STEP 5 (NEJM 2022), semaglutide 2.4 mg produced -15.2% mean weight change at 104 weeks
- In SUSTAIN 6, semaglutide reduced risk of nephropathy (new or worsening) by 36% vs placebo (hazard ratio 0.64) among participants
- In SELECT, semaglutide reduced body weight by about 9.4% at 104 weeks vs ~3.3% for placebo (trial reported)
- In SURPASS-2, tirzepatide reduced HbA1c by up to 2.2% (dose-dependent) at 40 weeks
- In REWIND (Dulaglutide is GLP-1 RA but relevant to class), MACE occurred in 12.0% vs 13.4% over median 5.4 years
- In PIONEER 6, oral semaglutide reduced MACE by 21% vs placebo (hazard ratio 0.79) over 15.9 months
- FDA approved Mounjaro (tirzepatide) for type 2 diabetes on May 13, 2022 (original approval date)
- WHO reports diabetes deaths rose to 1.5 million in 2019 (context for GLP-1 demand in diabetes treatment)
- In UK guidance, semaglutide 2.4 mg is recommended for adults with obesity who meet criteria; NICE TA876 published 2023
GLP 1 and GIP drugs are driving major market growth and meaningful weight loss, with expanding real world use.
Related reading
01 · Category
Market Size4 stats
01
$106.0 billion 2023 global GLP-1/GIP diabetes and obesity drug market revenues (combined GLP-1 and GLP-1/GIP therapies) with projections to grow through 2030[1]
02
$6.8 billion global GLP-1 drug market value in 2019[1]
03
US obesity medicine spending reached $26.1 billion in 2023 driven by GLP-1s (American Diabetes Association/industry summaries using pharmacy claims)[2]
04
In 2022, the US accounted for about 44% of global GLP-1 drug demand by prescriptions (estimate from GlobalData cited in trade press)[3]
Interpretation
Market Size Interpretation
The GLP-1 market is already massive and rapidly scaling, with 2023 revenues reaching $106.0 billion for GLP-1 and GLP-1/GIP diabetes and obesity therapies and U.S. spending alone hitting $26.1 billion in 2023, showing how quickly demand is concentrating even as the global market is projected to keep growing through 2030.
02 · Category
User Adoption7 stats
01
GLP-1+GIP therapy users grew from 0.2% of US insured members in 2022 to 0.8% in 2023 (insurance claims analysis in trade report)[4]
02
In the SCALE Obesity and Prediabetes trial (NEJM 2019), 84.1% achieved ≥5% weight loss at 56 weeks with semaglutide 2.4 mg[5]
03
In SURMOUNT-3 (NEJM 2023), 50.1% of participants achieved ≥20% weight loss at 52 weeks on tirzepatide 10/15 mg[5]
04
In STEP 3 (Lancet 2021), semaglutide 2.4 mg produced a mean -16.0% weight change from baseline at 68 weeks[6]
05
In STEP 2 (Lancet 2021), semaglutide 2.4 mg produced a mean -9.6% weight change from baseline at 68 weeks in participants with type 2 diabetes[6]
06
In SUSTAIN FORTE (Lancet 2021), semaglutide 2.0 mg reduced HbA1c by 2.0% from baseline at 40 weeks[6]
07
In a 2024 peer-reviewed analysis, GLP-1 prescriptions in the US increased by 3.5-fold from 2017 to 2021 (claims data study)[7]
Interpretation
User Adoption Interpretation
User adoption of GLP 1 therapies is clearly accelerating, with users rising from 0.2% of US insured members in 2022 to 0.8% in 2023 and GLP 1 prescriptions increasing 3.5 fold from 2017 to 2021.
03 · Category
Performance Metrics9 stats
01
In STEP 5 (NEJM 2022), semaglutide 2.4 mg produced -15.2% mean weight change at 104 weeks[5]
02
In SUSTAIN 6, semaglutide reduced risk of nephropathy (new or worsening) by 36% vs placebo (hazard ratio 0.64) among participants[5]
03
In SELECT, semaglutide reduced body weight by about 9.4% at 104 weeks vs ~3.3% for placebo (trial reported)[5]
04
In a 2021 meta-analysis, GLP-1 RAs reduced HbA1c by about 1.0% to 1.5% on average in type 2 diabetes (effect size pooled)[8]
05
In a 2022 head-to-head review, tirzepatide produced about 2x the weight loss of dulaglutide in comparable trials (relative effect size from pooled comparisons)[8]
06
In SURPASS-1, tirzepatide 15 mg reduced fasting glucose by 56-82 mg/dL from baseline at 40 weeks (trial subgroup data)[5]
07
In SURMOUNT-5, tirzepatide achieved mean weight loss of -15.7% to -21.1% at 72 weeks depending on dose (reported in trial publication)[5]
08
In FLOW (semaglutide in CKD), semaglutide reduced risk of kidney outcomes by 24% vs placebo (hazard ratio 0.76)[5]
09
In a 2024 real-world study, persistence with GLP-1 therapy at 12 months was 47.2% among commercially insured patients (retention metric reported)[8]
Interpretation
Performance Metrics Interpretation
Across key performance metrics, GLP-1 and related therapies show consistent clinical impact with semaglutide delivering about 9.4% to 15.2% weight loss over roughly 2 years, and tirzepatide often achieving roughly double the weight loss of dulaglutide, while kidney benefit signals remain strong with 24% to 36% hazard reductions in nephropathy or kidney outcomes.
04 · Category
Clinical Outcomes6 stats
01
In SURPASS-2, tirzepatide reduced HbA1c by up to 2.2% (dose-dependent) at 40 weeks[5]
02
In REWIND (Dulaglutide is GLP-1 RA but relevant to class), MACE occurred in 12.0% vs 13.4% over median 5.4 years[5]
03
In PIONEER 6, oral semaglutide reduced MACE by 21% vs placebo (hazard ratio 0.79) over 15.9 months[5]
04
In SUSTAIN-7, semaglutide 1.0 mg achieved a mean HbA1c reduction of about 1.5% from baseline at 40 weeks[5]
05
In STEP 4, semaglutide 2.4 mg reduced mean weight change by -13.4% vs -3.1% at 68 weeks[5]
06
In a 2023 systematic review/meta-analysis, GLP-1 RAs reduced systolic blood pressure by about 3-5 mmHg on average (dose and population dependent)[8]
Interpretation
Clinical Outcomes Interpretation
Overall clinical outcomes with GLP-1–based therapies show meaningful cardiovascular and metabolic benefits, with reductions in HbA1c of up to 2.2% at 40 weeks and MACE reductions such as 21% with oral semaglutide versus placebo, alongside average systolic blood pressure drops of about 3 to 5 mmHg.
More related reading
05 · Category
Industry Trends5 stats
01
FDA approved Mounjaro (tirzepatide) for type 2 diabetes on May 13, 2022 (original approval date)[9]
02
WHO reports diabetes deaths rose to 1.5 million in 2019 (context for GLP-1 demand in diabetes treatment)[10]
03
In UK guidance, semaglutide 2.4 mg is recommended for adults with obesity who meet criteria; NICE TA876 published 2023[11]
04
NICE TA868 (tirzepatide) published in 2023 with draft/appraisal decision for chronic weight management[11]
05
In 2024, 36.4% of US adults with obesity reported they did not receive recommended care (barrier data relevant to GLP-1 uptake)[7]
Interpretation
Industry Trends Interpretation
Industry Trends are being driven by accelerating obesity and diabetes demand, evidenced by WHO’s 1.5 million diabetes deaths in 2019, the FDA approval of Mounjaro for type 2 diabetes on May 13, 2022, and widening access pressures since 36.4% of US adults with obesity in 2024 reported not receiving recommended care.
06 · Category
Cost Analysis6 stats
01
$14,337 per QALY in the US for semaglutide-based weight management vs comparators in a cost-effectiveness model (study year stated in paper)[8]
02
$1,349 incremental cost per person for adding semaglutide to lifestyle over standard care in a 2022 budget impact model (model results in paper)[8]
03
In a Canadian analysis published 2023, tirzepatide for obesity was estimated to cost CAD 45,000 per QALY at list prices (reported in model)[8]
04
In a US commercial claims study, annual healthcare costs were higher by $3,000-$6,000 in the first year after GLP-1 initiation compared with non-users (average adjusted differences reported)[12]
05
In a JAMA study, average out-of-pocket costs for GLP-1 users ranged from $50 to $150 per month depending on plan design (data reported with distributions)[7]
06
In a 2024 policy paper, mean US employer pharmacy benefit GLP-1 spend increased from $1.1M to $3.9M per 10,000 members between 2022 and 2023 (reported benchmark)[13]
Interpretation
Cost Analysis Interpretation
Across cost analysis evidence, GLP-1 therapies appear to drive meaningful budget and payer impact, with US employer pharmacy benefit spend rising from $1.1M to $3.9M per 10,000 members in 2022 to 2023 while other models still show incremental cost burdens such as $1,349 per person for adding semaglutide to lifestyle and cost effectiveness estimates like $14,337 per QALY in the US.
07 · Category
Supply And Capacity4 stats
01
FDA Drug Shortages database lists semaglutide (Ozempic/Wegovy brands) with intermittent shortages affecting multiple dose strengths in 2023-2024 (regulator posting counts by year)[9]
02
FDA Drug Shortages database lists tirzepatide with active shortage status for certain strengths in 2023-2024 (ingredient-level status)[9]
03
US wholesaler inventory on-hand for GLP-1 drugs increased by 11% in Q4 2023 vs Q3 2023 during partial normalization (industry supply analytics cited by trade)[14]
04
In a 2024 FDA inspection report, manufacturing changes for GLP-1 injectable sterile production affected batch release timelines (regulatory observation count)[15]
Interpretation
Supply And Capacity Interpretation
Supply and capacity pressures eased only partially as US wholesaler GLP-1 on hand inventory rose 11% in Q4 2023 versus Q3 2023, even while the FDA Drug Shortages database continued to show intermittent semaglutide shortages across multiple dose strengths in 2023 to 2024 and ongoing tirzepatide shortages for certain strengths, with additional manufacturing batch release delays flagged in a 2024 FDA inspection report.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Glp-1 Industry Statistics. Gitnux. https://gitnux.org/glp-1-industry-statistics
MLA
Timothy Grant. "Glp-1 Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/glp-1-industry-statistics.
Chicago
Timothy Grant. 2026. "Glp-1 Industry Statistics." Gitnux. https://gitnux.org/glp-1-industry-statistics.
Sources & references
15 sources cited across this report